The total number of records retrieved from this search are 15. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_629	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 3 Gy (antagonism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineDO4	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.001 MOI	In-vitro result120% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_630	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 3 Gy (antagonism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineDO4	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result110% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_631	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 3 Gy (antagonism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineDO4	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result60% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_632	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 3 Gy (antagonism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineDO4	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result40% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_633	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 3 Gy (antagonism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineDO4	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result30% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_634	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 5 Gy (antagonism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineDO4	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.001 MOI	In-vitro result110% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_635	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 5 Gy (antagonism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineDO4	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result70% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_636	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 5 Gy (antagonism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineDO4	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result58% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_637	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 5 Gy (antagonism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineDO4	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result25% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_638	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 5 Gy (antagonism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineDO4	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result25% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_684	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineDO4	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.001 MOI	In-vitro result120% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_685	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineDO4	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result105% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_686	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineDO4	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result77% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_687	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineDO4	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result50% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_688	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineDO4	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result30% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486